Vesa Cheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Vesa Cheng has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Jason Alexander Roberts
University of Queensland Centre for Clinical Research, The University of Queensland, Brisbane, Australia
3 shared publications David Zacharias
Department of Intensive Care Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
2 shared publications- Mohd Hafiz Abdul-Aziz
University of Queensland Centre for Clinical Research (UQCCR), Faculty of Medicine, The University of Queensland, Brisbane, Australia
2 shared publications Sam Rudham
Department of Intensive Care Medicine, St Vincent’s Hospital, Sydney, New South Wales, Australia
2 shared publicationsAmanda Corley
Adult Intensive Care Services, the Prince Charles Hospital, Chermside, Australia
1 shared publication- Amanda Corley
School of Nursing and Midwifery, Griffith University, Nathan, Australia; Nursing and Midwifery Research Centre, Royal Brisbane and Women's Hospital, Herston, Australia; Division of Surgery, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
1 shared publication
Latest Publications
- 12 September 2025
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2025 (9) , CD003281
Stimulation of the wrist acupuncture point PC6 for preventing postoperative nausea and vomiting: a network meta-analysis
Postoperative nausea and vomiting (PONV) are common complications following surgery and anaesthesia. Antiemetic drugs are only partially effective in preventing PONV. Stimulating the PC6 acupoint(s) on the wrist offers an alternative approach, but the effectiveness of the various common techniques is unclear. To update and compare the effects and safety of PC6 acupoint stimulation with or without antiemetic drug(s) versus sham or antiemetic drug(s) for preventing postoperative nausea (PON) and postoperative vomiting (POV) in people undergoing surgery, and to identify the most effective techniques using network meta-analyses (NMAs). We searched CENTRAL, MEDLINE, Embase, ISI Web of Science, CINAHL, WHO Global Index Medicus, major trial registries, and reference lists of articles for studies up to 6 June 2025, with no language restrictions. Parallel randomised controlled trials of techniques that compared any combinations of PC6 acupoint stimulation, drug therapy, and sham for preventing PONV in children and adults were eligible. Interventions included invasive techniques (e.g. needle acupuncture) and noninvasive techniques (e.g. acupressure wristbands). Drug therapy included antiemetics that belonged to one of the following substance classes: 5-HT3 receptor antagonists, D2 receptor antagonists, corticosteroids, and antihistamines. The sham group included sham PC6 interventions and/or placebo saline antiemetic interventions. Critical outcomes: incidence of PON and POV. Important outcomes: need for rescue antiemetic therapy when prophylaxis failed and adverse events (side effects). We assessed the risk of bias in the included studies using RoB 1. We performed frequentist NMAs using random-effects models to report risk ratios (RRs) with 95% confidence intervals (95% CIs). We compared the relative effects (with sham as reference) of six broad classes of PC6 acupoint stimulation techniques and their combined use with antiemetic drugs on the outcomes. We summarised the safety data narratively due to heterogeneous reporting of adverse events (side effects). We assessed the certainty of evidence of the NMA treatment effect on outcomes according to the CINeMA and GRADE approaches. This update included 77 trials, conducted between 1986 and 2022, involving 9847 participants. The majority were adults across several countries (USA, South Korea, India, China, Turkey, and Iran). There were 58 (33.9%) sham groups, 16 (9.4%) invasive PC6 acupoint stimulation groups, 50 (29.3%) noninvasive PC6 acupoint stimulation groups, 32 (18.7%) antiemetic(s) groups, 4 (2.3%) combined invasive PC6 acupoint stimulation and antiemetic(s) groups, 10 (5.8%) combined noninvasive PC6 acupoint stimulation and antiemetic(s) groups, and one (0.6%) combined invasive and noninvasive PC6 acupoint stimulation group for the NMAs. The high risk of bias was primarily due to selective reporting. Postoperative nausea The evidence from the NMA (63 studies; 7534 participants) suggests that the combined invasive PC6 and antiemetics technique probably results in a larger reduction in PON than sham (RR 0.21, 95% CI 0.10 to 0.45; moderate confidence from indirect evidence only). The evidence also suggests that invasive PC6, noninvasive PC6, and antiemetic(s) may reduce PON, compared to sham (invasive PC6: RR 0.49, 95% CI 0.38 to 0.64, low confidence; noninvasive PC6: RR 0.67, 95% CI 0.58 to 0.76, low confidence; antiemetic(s): RR 0.73, 95% CI 0.59 to 0.91, very low confidence). The combined use of noninvasive PC6 and antiemetic(s) may reduce PON, compared to sham, based on indirect evidence (RR 0.65, 95% CI 0.45 to 0.96; low confidence). Postoperative vomiting The evidence from the NMA (75 studies; 8627 participants) suggests that the combined invasive PC6 and antiemetics technique may result in a moderate reduction in POV, compared to sham (RR 0.37, 95% CI 0.18 to 0.76; low confidence from indirect evidence only). The evidence also suggests that invasive PC6, noninvasive PC6, antiemetic(s), and combined noninvasive PC6 and antiemetic(s) may reduce POV, compared to sham (invasive PC6: RR 0.47, 95% CI 0.34 to 0.64, low confidence; noninvasive PC6: RR 0.58, 95% CI 0.49 to 0.70, low confidence; antiemetic(s): RR 0.62, 95% CI 0.47 to 0.81, very low confidence; combined noninvasive PC6 and antiemetic(s): RR 0.52, 95% CI 0.33 to 0.83, very low confidence). The combined use of noninvasive PC6 and invasive PC6 may result in little to no difference in POV, compared to sham, based on direct evidence (RR 1.02, 95% CI 0.43 to 2.44; low confidence). Need for rescue antiemetic drug(s) The evidence from the NMA (55 studies; 6614 participants) suggests that combined use of noninvasive PC6 and antiemetic(s) probably reduces the need for rescue antiemetic drug(s) when prophylactic techniques fail, compared to sham (RR 0.44, 95% CI 0.28 to 0.70; moderate confidence from indirect evidence). Antiemetic(s), noninvasive PC6, and invasive PC6 may reduce the need for rescue antiemetics, compared to sham (antiemetic(s): RR 0.56, 95% CI 0.40 to 0.80, very low confidence; noninvasive PC6: RR 0.60, 95% CI 0.51 to 0.70, low confidence; invasive PC6: RR 0.61, 95% CI 0.44 to 0.84, low confidence). The combined use of invasive PC6 and antiemetic(s) (RR 0.31, 95% CI 0.04 to 2.49; low confidence from indirect evidence only) and the combined use of noninvasive PC6 and invasive PC6 may result in little or no difference in the need for rescue antiemetic drug(s), compared to sham (RR 1.41, 95% CI 0.64 to 3.09; low confidence from direct evidence only). Adverse events (side effects) None of the included studies reported serious or long-term complications. Thirty-nine studies, involving 5334 participants, reported minor side effects that go away (e.g. skin irritation, redness, and swelling) with PC6 acupoint stimulation, but the evidence is very uncertain. Publication bias was not apparent in the NMA funnel plots. NMAs suggest that both invasive and noninvasive PC6 acupoint stimulation combined with antiemetics may reduce PON and POV, compared to sham, and likely lower rescue antiemetic use. PC6 acupoint stimulation may cause minor side effects, but the evidence is very uncertain. This updated Cochrane review was partially funded by the Cochrane Complementary Medicine Field Bursary 2020 from the National Center for Complementary and Alternative Medicine, National Institutes of Health (Grant Number R24 AT001293). Protocol (2001): doi.org/10.1002/14651858.CD003281 Original review (2004): doi.org/10.1002/14651858.CD003281.pub2 Update review (2009): doi.org/10.1002/14651858.CD003281.pub3 Update review (2015): doi.org/10.1002/14651858.CD003281.pub4.
- 12 September 2025
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2025 (9) , CD003281
Stimulation of the wrist acupuncture point PC6 for preventing postoperative nausea and vomiting: a network meta-analysis
Postoperative nausea and vomiting (PONV) are common complications following surgery and anaesthesia. Antiemetic drugs are only partially effective in preventing PONV. Stimulating the PC6 acupoint(s) on the wrist offers an alternative approach, but the effectiveness of the various common techniques is unclear. To update and compare the effects and safety of PC6 acupoint stimulation with or without antiemetic drug(s) versus sham or antiemetic drug(s) for preventing postoperative nausea (PON) and postoperative vomiting (POV) in people undergoing surgery, and to identify the most effective techniques using network meta-analyses (NMAs). We searched CENTRAL, MEDLINE, Embase, ISI Web of Science, CINAHL, WHO Global Index Medicus, major trial registries, and reference lists of articles for studies up to 6 June 2025, with no language restrictions. Parallel randomised controlled trials of techniques that compared any combinations of PC6 acupoint stimulation, drug therapy, and sham for preventing PONV in children and adults were eligible. Interventions included invasive techniques (e.g. needle acupuncture) and noninvasive techniques (e.g. acupressure wristbands). Drug therapy included antiemetics that belonged to one of the following substance classes: 5-HT3 receptor antagonists, D2 receptor antagonists, corticosteroids, and antihistamines. The sham group included sham PC6 interventions and/or placebo saline antiemetic interventions. Critical outcomes: incidence of PON and POV. Important outcomes: need for rescue antiemetic therapy when prophylaxis failed and adverse events (side effects). We assessed the risk of bias in the included studies using RoB 1. We performed frequentist NMAs using random-effects models to report risk ratios (RRs) with 95% confidence intervals (95% CIs). We compared the relative effects (with sham as reference) of six broad classes of PC6 acupoint stimulation techniques and their combined use with antiemetic drugs on the outcomes. We summarised the safety data narratively due to heterogeneous reporting of adverse events (side effects). We assessed the certainty of evidence of the NMA treatment effect on outcomes according to the CINeMA and GRADE approaches. This update included 77 trials, conducted between 1986 and 2022, involving 9847 participants. The majority were adults across several countries (USA, South Korea, India, China, Turkey, and Iran). There were 58 (33.9%) sham groups, 16 (9.4%) invasive PC6 acupoint stimulation groups, 50 (29.3%) noninvasive PC6 acupoint stimulation groups, 32 (18.7%) antiemetic(s) groups, 4 (2.3%) combined invasive PC6 acupoint stimulation and antiemetic(s) groups, 10 (5.8%) combined noninvasive PC6 acupoint stimulation and antiemetic(s) groups, and one (0.6%) combined invasive and noninvasive PC6 acupoint stimulation group for the NMAs. The high risk of bias was primarily due to selective reporting. Postoperative nausea The evidence from the NMA (63 studies; 7534 participants) suggests that the combined invasive PC6 and antiemetics technique probably results in a larger reduction in PON than sham (RR 0.21, 95% CI 0.10 to 0.45; moderate confidence from indirect evidence only). The evidence also suggests that invasive PC6, noninvasive PC6, and antiemetic(s) may reduce PON, compared to sham (invasive PC6: RR 0.49, 95% CI 0.38 to 0.64, low confidence; noninvasive PC6: RR 0.67, 95% CI 0.58 to 0.76, low confidence; antiemetic(s): RR 0.73, 95% CI 0.59 to 0.91, very low confidence). The combined use of noninvasive PC6 and antiemetic(s) may reduce PON, compared to sham, based on indirect evidence (RR 0.65, 95% CI 0.45 to 0.96; low confidence). Postoperative vomiting The evidence from the NMA (75 studies; 8627 participants) suggests that the combined invasive PC6 and antiemetics technique may result in a moderate reduction in POV, compared to sham (RR 0.37, 95% CI 0.18 to 0.76; low confidence from indirect evidence only). The evidence also suggests that invasive PC6, noninvasive PC6, antiemetic(s), and combined noninvasive PC6 and antiemetic(s) may reduce POV, compared to sham (invasive PC6: RR 0.47, 95% CI 0.34 to 0.64, low confidence; noninvasive PC6: RR 0.58, 95% CI 0.49 to 0.70, low confidence; antiemetic(s): RR 0.62, 95% CI 0.47 to 0.81, very low confidence; combined noninvasive PC6 and antiemetic(s): RR 0.52, 95% CI 0.33 to 0.83, very low confidence). The combined use of noninvasive PC6 and invasive PC6 may result in little to no difference in POV, compared to sham, based on direct evidence (RR 1.02, 95% CI 0.43 to 2.44; low confidence). Need for rescue antiemetic drug(s) The evidence from the NMA (55 studies; 6614 participants) suggests that combined use of noninvasive PC6 and antiemetic(s) probably reduces the need for rescue antiemetic drug(s) when prophylactic techniques fail, compared to sham (RR 0.44, 95% CI 0.28 to 0.70; moderate confidence from indirect evidence). Antiemetic(s), noninvasive PC6, and invasive PC6 may reduce the need for rescue antiemetics, compared to sham (antiemetic(s): RR 0.56, 95% CI 0.40 to 0.80, very low confidence; noninvasive PC6: RR 0.60, 95% CI 0.51 to 0.70, low confidence; invasive PC6: RR 0.61, 95% CI 0.44 to 0.84, low confidence). The combined use of invasive PC6 and antiemetic(s) (RR 0.31, 95% CI 0.04 to 2.49; low confidence from indirect evidence only) and the combined use of noninvasive PC6 and invasive PC6 may result in little or no difference in the need for rescue antiemetic drug(s), compared to sham (RR 1.41, 95% CI 0.64 to 3.09; low confidence from direct evidence only). Adverse events (side effects) None of the included studies reported serious or long-term complications. Thirty-nine studies, involving 5334 participants, reported minor side effects that go away (e.g. skin irritation, redness, and swelling) with PC6 acupoint stimulation, but the evidence is very uncertain. Publication bias was not apparent in the NMA funnel plots. NMAs suggest that both invasive and noninvasive PC6 acupoint stimulation combined with antiemetics may reduce PON and POV, compared to sham, and likely lower rescue antiemetic use. PC6 acupoint stimulation may cause minor side effects, but the evidence is very uncertain. This updated Cochrane review was partially funded by the Cochrane Complementary Medicine Field Bursary 2020 from the National Center for Complementary and Alternative Medicine, National Institutes of Health (Grant Number R24 AT001293). Protocol (2001): doi.org/10.1002/14651858.CD003281 Original review (2004): doi.org/10.1002/14651858.CD003281.pub2 Update review (2009): doi.org/10.1002/14651858.CD003281.pub3 Update review (2015): doi.org/10.1002/14651858.CD003281.pub4.
- 13 July 2025
- Published by Taylor & Francis in Journal of Interprofessional Care
- p. 1-7
A comprehensive whole-of-health service approach to interprofessional collaboration
Interprofessional education (IPE) and interprofessional collaborative practice (IPCP) are essential for high-quality safe, effective, and efficient healthcare. This program of work aimed to build a culture of IPE and IPCP across a large metropolitan health service. This study was a repeated cross-sectional study which evaluated an approach to integrating IPE and IPCP as an embedded model of care across a health service. The Interprofessional Collaborative Organisation Map and Preparedness Assessment (IP-COMPASS) was used to (i) understand the current state of IPE and IPCP across the organization, (ii) guide a cohesive and comprehensive program of work to implement systems, structures, governance, practices, and education that support and develop IPE and IPCP, and (iii) evaluate the change in IPE and IPCP following the program of work. Eleven out of 22 interprofessional attributes (50%) were weak or absent at baseline. Following 18-months implementation of targeted interprofessional initiatives, strategies, and education, five attributes (22%) were weak or absent. Thirteen attributes improved (59%), six remained the same (27%), and three declined (14%). Many interprofessional attributes improved with a program of initiatives targeted to enhance the systems, structures, governance, practices, and education that support and develop IPE and IPCP. A small number of attributes declined, which may reflect increased awareness of IPE and IPCP as a previously unrecognized gap, leading to the realization that this critical way of working is absent. Despite improvements, many interprofessional attributes remained inadequate, highlighting the challenges and extended timeframes required for systems level change.
- 13 July 2025
- Published by Taylor & Francis in Journal of Interprofessional Care
- p. 1-7
A comprehensive whole-of-health service approach to interprofessional collaboration
Interprofessional education (IPE) and interprofessional collaborative practice (IPCP) are essential for high-quality safe, effective, and efficient healthcare. This program of work aimed to build a culture of IPE and IPCP across a large metropolitan health service. This study was a repeated cross-sectional study which evaluated an approach to integrating IPE and IPCP as an embedded model of care across a health service. The Interprofessional Collaborative Organisation Map and Preparedness Assessment (IP-COMPASS) was used to (i) understand the current state of IPE and IPCP across the organization, (ii) guide a cohesive and comprehensive program of work to implement systems, structures, governance, practices, and education that support and develop IPE and IPCP, and (iii) evaluate the change in IPE and IPCP following the program of work. Eleven out of 22 interprofessional attributes (50%) were weak or absent at baseline. Following 18-months implementation of targeted interprofessional initiatives, strategies, and education, five attributes (22%) were weak or absent. Thirteen attributes improved (59%), six remained the same (27%), and three declined (14%). Many interprofessional attributes improved with a program of initiatives targeted to enhance the systems, structures, governance, practices, and education that support and develop IPE and IPCP. A small number of attributes declined, which may reflect increased awareness of IPE and IPCP as a previously unrecognized gap, leading to the realization that this critical way of working is absent. Despite improvements, many interprofessional attributes remained inadequate, highlighting the challenges and extended timeframes required for systems level change.
- 4 April 2025
- Published by Wiley in Hemodialysis International
- Vol. 29 (4) , 713-716
Pharmacokinetics of Metronidazole During Prolonged Intermittent Kidney Replacement Therapy
Acute kidney injury is a common complication present in critically ill patients and is often managed by kidney replacement therapy. Prolonged intermittent kidney replacement therapy (PIKRT) is a modality of kidney replacement therapy often utilized in intensive care settings, but dosing recommendations and pharmacokinetic data for antimicrobial removal during PIKRT are limited. Metronidazole, a 5‐nitroimidazole agent, is commonly prescribed for anaerobic and protozoal infections. Although generally well tolerated, adverse effects including severe neurotoxicity have been reported in association with prolonged or high cumulative dosing, particularly in the setting of kidney or hepatic impairment. In this case study, we describe and discuss the pharmacokinetics of metronidazole and the hydroxy‐metabolite (hydroxy‐metronidazole) concentrations in a critically ill patient undergoing PIKRT.
- 4 April 2025
- Published by Wiley in Hemodialysis International
- Vol. 29 (4) , 713-716
Pharmacokinetics of Metronidazole During Prolonged Intermittent Kidney Replacement Therapy
Acute kidney injury is a common complication present in critically ill patients and is often managed by kidney replacement therapy. Prolonged intermittent kidney replacement therapy (PIKRT) is a modality of kidney replacement therapy often utilized in intensive care settings, but dosing recommendations and pharmacokinetic data for antimicrobial removal during PIKRT are limited. Metronidazole, a 5‐nitroimidazole agent, is commonly prescribed for anaerobic and protozoal infections. Although generally well tolerated, adverse effects including severe neurotoxicity have been reported in association with prolonged or high cumulative dosing, particularly in the setting of kidney or hepatic impairment. In this case study, we describe and discuss the pharmacokinetics of metronidazole and the hydroxy‐metabolite (hydroxy‐metronidazole) concentrations in a critically ill patient undergoing PIKRT.
- Open Access
- 30 October 2024
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 6 (6) , dlae186
A review of antimicrobial stability testing guidance for outpatient parenteral antimicrobial therapy programmes: is it time for global harmonization of testing frameworks?
Antimicrobial stability is an important consideration for treatment planning and service delivery in outpatient parenteral antimicrobial therapy (OPAT) programmes. Regulation of stability assessment varies by region, and conflicting guidance and standards exist. This leads to disparity of equity in access and limits availability of certain antimicrobials for managing infections in the outpatient setting. This review discusses the degree to which the international regulatory bodies have reached consensus on the regulation of antimicrobial stability testing, specifically for OPAT, and describes the variation in antimicrobial recommendations across regulatory bodies. The three major findings in this review are (i) variation in antimicrobial stability testing guidance, particularly in relation to temperature; (ii) lack of regulatory guidance, specifically in that some regions did not have OPAT guidelines; and (iii) only the UK’s NHS has provided non-regulatory OPAT-specific advice on antimicrobial stability testing. In conclusion, harmonization of antimicrobial stability testing to form a global OPAT-specific regulatory framework, particularly considering ‘areas of variation’ amongst current guidance, is required. We call for the development of a global OPAT antimicrobial stability testing framework with consensus from accepted antimicrobial stability criteria, expert opinion and pharmacopoeial best practice.
- 30 October 2024
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 6 (6) , dlae186
Open AccessA review of antimicrobial stability testing guidance for outpatient parenteral antimicrobial therapy programmes: is it time for global harmonization of testing frameworks?
Antimicrobial stability is an important consideration for treatment planning and service delivery in outpatient parenteral antimicrobial therapy (OPAT) programmes. Regulation of stability assessment varies by region, and conflicting guidance and standards exist. This leads to disparity of equity in access and limits availability of certain antimicrobials for managing infections in the outpatient setting. This review discusses the degree to which the international regulatory bodies have reached consensus on the regulation of antimicrobial stability testing, specifically for OPAT, and describes the variation in antimicrobial recommendations across regulatory bodies. The three major findings in this review are (i) variation in antimicrobial stability testing guidance, particularly in relation to temperature; (ii) lack of regulatory guidance, specifically in that some regions did not have OPAT guidelines; and (iii) only the UK’s NHS has provided non-regulatory OPAT-specific advice on antimicrobial stability testing. In conclusion, harmonization of antimicrobial stability testing to form a global OPAT-specific regulatory framework, particularly considering ‘areas of variation’ amongst current guidance, is required. We call for the development of a global OPAT antimicrobial stability testing framework with consensus from accepted antimicrobial stability criteria, expert opinion and pharmacopoeial best practice.
- 18 January 2022
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 66 (1) , e0137721
Population Pharmacokinetics of Vancomycin in Critically Ill Adult Patients Receiving Extracorporeal Membrane Oxygenation (an ASAP ECMO Study)
Our study aimed to describe the population pharmacokinetics (PK) of vancomycin in critically ill patients receiving extracorporeal membrane oxygenation (ECMO), including those receiving concomitant renal replacement therapy (RRT). Dosing simulations were used to recommend maximally effective and safe dosing regimens.
- 18 January 2022
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 66 (1) , e0137721
Population Pharmacokinetics of Vancomycin in Critically Ill Adult Patients Receiving Extracorporeal Membrane Oxygenation (an ASAP ECMO Study)
Our study aimed to describe the population pharmacokinetics (PK) of vancomycin in critically ill patients receiving extracorporeal membrane oxygenation (ECMO), including those receiving concomitant renal replacement therapy (RRT). Dosing simulations were used to recommend maximally effective and safe dosing regimens.
- 20 December 2021
- Published by University of Queensland Library
Optimising antimicrobial dosing in critically ill patients on extracorporeal membrane oxygenation (ECMO)
The University of Queensland's institutional repository, UQ eSpace, aims to create global visibility and accessibility of UQ’s scholarly research.
- 20 December 2021
- Published by University of Queensland Library
Optimising antimicrobial dosing in critically ill patients on extracorporeal membrane oxygenation (ECMO)
The University of Queensland's institutional repository, UQ eSpace, aims to create global visibility and accessibility of UQ’s scholarly research.
- 1 December 2021
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 58 (6) , 106466
Population pharmacokinetics of cefepime in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study)
- 1 December 2021
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 58 (6) , 106466
Population pharmacokinetics of cefepime in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study)